CA2177179A1 - Antagonists to chaperonin 10 - Google Patents

Antagonists to chaperonin 10

Info

Publication number
CA2177179A1
CA2177179A1 CA002177179A CA2177179A CA2177179A1 CA 2177179 A1 CA2177179 A1 CA 2177179A1 CA 002177179 A CA002177179 A CA 002177179A CA 2177179 A CA2177179 A CA 2177179A CA 2177179 A1 CA2177179 A1 CA 2177179A1
Authority
CA
Canada
Prior art keywords
cpn10
sample
antibody
antidoby
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002177179A
Other languages
French (fr)
Other versions
CA2177179C (en
Inventor
Halle Morton
Alice Christina Cavanagh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Queensland UQ
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPM8234A external-priority patent/AUPM823494A0/en
Application filed by Individual filed Critical Individual
Publication of CA2177179A1 publication Critical patent/CA2177179A1/en
Application granted granted Critical
Publication of CA2177179C publication Critical patent/CA2177179C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4715—Pregnancy proteins, e.g. placenta proteins, alpha-feto-protein, pregnancy specific beta glycoprotein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)

Abstract

A method of suppressiom of cellular growth or enhancing immunological activity including the administration of cpn10 antag-onists or anti-cpn10 antidoby to a subject. There is also provided antagonists to or antibody raised against cpn10 or a recom-binant cpn10 which has the amino acid sequence GSAGQAFRKFLPLFDRVLVERSAAETVTKGGIMLPEKSQGKVLQATVEAVGS-GSKGKGGEIQPVSVKEGDKVLLPEYGGTKVVLDDKDYFLFRDGDILGKYVD. There is also provided an assay for measuring anti-cpn10 antidoby in a sample including the steps of 1) reacting substantially purified cpn10 with the sample; and 2) determination of the amount of anti-cpn10 antibody in the sample by determining the binding between the antibody and cpn10.
CA002177179A 1993-11-30 1994-11-30 Antagonists to chaperonin 10 Expired - Fee Related CA2177179C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AUPM270593 1993-11-30
AUPM2705 1993-11-30
AUPM8234A AUPM823494A0 (en) 1994-09-16 1994-09-16 Diagnostic and therapeutic uses of chaperonin 10
AUPM8234 1994-09-16
PCT/AU1994/000742 WO1995015339A1 (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10

Publications (2)

Publication Number Publication Date
CA2177179A1 true CA2177179A1 (en) 1995-06-08
CA2177179C CA2177179C (en) 2006-10-17

Family

ID=25644587

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002177179A Expired - Fee Related CA2177179C (en) 1993-11-30 1994-11-30 Antagonists to chaperonin 10

Country Status (11)

Country Link
US (3) US6113899A (en)
EP (2) EP0731811B1 (en)
JP (3) JP3545408B2 (en)
AT (1) ATE282634T1 (en)
AU (2) AU684578B2 (en)
CA (1) CA2177179C (en)
DE (1) DE69434137T2 (en)
ES (1) ES2233938T3 (en)
NZ (2) NZ276672A (en)
PT (1) PT731811E (en)
WO (2) WO1995015339A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT731811E (en) * 1993-11-30 2005-04-29 Univ Queensland CHAPERONINE 10
AU751359B2 (en) * 1997-07-10 2002-08-15 Medical Research Council Chaperone fragments
US6007821A (en) * 1997-10-16 1999-12-28 Fordham University Method and compositions for the treatment of autoimmune disease using heat shock proteins
US6475490B1 (en) 1998-10-19 2002-11-05 Fordham University Compositions and methods for promoting tissue repair using heat shock proteins
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
GB0028122D0 (en) * 2000-11-17 2001-01-03 St Georges Entpr Ltd Method
JP4326326B2 (en) * 2001-06-27 2009-09-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ EPF receptor assays, compounds and therapeutic compositions
AU2002952492A0 (en) 2002-11-06 2002-11-21 Cbio Limited Chaperonin 10 immunosuppression
GB0226105D0 (en) * 2002-11-08 2002-12-18 St Georges S Entpr Ltd Pain relief agents
NZ548985A (en) * 2004-01-16 2010-02-26 Cbio Ltd Chaperonin 10 modulation of toll-like receptor-inducible cytokine and chemokine secretion
NZ566817A (en) * 2005-08-31 2012-02-24 Cbio Ltd Modified chaperonin 10, wherein the N-terminus comprises a single additional glycine residue compared to a corresponding mammalian wild-type
EP1951282A4 (en) * 2005-10-20 2009-09-02 Cbio Ltd Treatment of hypersensitivity
AU2006303826B2 (en) * 2005-10-20 2012-07-19 Cbio Limited Treatment of hypersensitivity
CA2644058C (en) * 2006-03-02 2016-08-09 Cbio Limited Regulation of immune responses by modulation of the function of antigen presenting cells
WO2009124353A1 (en) 2008-04-11 2009-10-15 Cbio Limited Modified cpn10 and prr signalling
EP2485753A4 (en) * 2009-10-09 2013-12-11 Cbio Ltd Chaperonin 10 variants
US20110243921A1 (en) * 2010-03-30 2011-10-06 Cbio Limited Prevention and treatment of cutaneous lupus erythematosus

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986005498A1 (en) * 1985-03-12 1986-09-25 University Of Queensland Method for detecting early pregnancy factor (epf) in mammals, purifying epf and method for producing a monoclonal antibody
AU599021B2 (en) * 1985-03-12 1990-07-12 University Of Queensland, The Method for detecting early pregnancy factor (epf) in mammals,purifying epf and method for producing a monoclonal antibody
EP0345260A4 (en) * 1986-12-22 1990-05-14 Univ Queensland Method of treatment of mammals using antibodies to early pregnancy factor (epf).
AU1086988A (en) * 1986-12-22 1988-07-15 University Of Queensland, The Method of treatment of mammals using antibodies to early pregnancy factor (epf)
PT731811E (en) * 1993-11-30 2005-04-29 Univ Queensland CHAPERONINE 10

Also Published As

Publication number Publication date
AU1103495A (en) 1995-06-19
NZ276670A (en) 1998-01-26
EP0733071A1 (en) 1996-09-25
JPH09506431A (en) 1997-06-24
WO1995015338A1 (en) 1995-06-08
AU1103695A (en) 1995-06-19
PT731811E (en) 2005-04-29
JP2004067698A (en) 2004-03-04
US6417334B1 (en) 2002-07-09
JP3987104B2 (en) 2007-10-03
US6113899A (en) 2000-09-05
CA2177179C (en) 2006-10-17
EP0731811B1 (en) 2004-11-17
JPH09505811A (en) 1997-06-10
WO1995015339A1 (en) 1995-06-08
US7358329B2 (en) 2008-04-15
JP3986481B2 (en) 2007-10-03
EP0731811A4 (en) 2003-05-28
DE69434137D1 (en) 2004-12-23
EP0731811A1 (en) 1996-09-18
ATE282634T1 (en) 2004-12-15
ES2233938T3 (en) 2005-06-16
EP0733071A4 (en) 1997-02-26
AU684577B2 (en) 1997-12-18
DE69434137T2 (en) 2005-12-01
US20030175280A1 (en) 2003-09-18
AU684578B2 (en) 1997-12-18
JP3545408B2 (en) 2004-07-21
NZ276672A (en) 1998-01-26

Similar Documents

Publication Publication Date Title
CA2177179A1 (en) Antagonists to chaperonin 10
CA2140794A1 (en) Assay for the determination of protein in a biological sample
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
AU616156B2 (en) Monoclonal antibodies and peptides useful in treating and diagnosing HIV infections
EP0869177A3 (en) Human a- and b- platelet-derived growth factor receptor proteins and uses therefor.
DE68905313D1 (en) ENZYME IMMUNOASSAY FOR MEASURING CYCLOSPORIN-A MIRRORS IN WHOLE BLOOD SAMPLES.
CA2193323A1 (en) Process for preparing a synthetic calibrator for use in sandwich immunoassays, which calibrator consists of an antibody against one of the antibodies used in the assay and of a sequence of the analyte
KR880012768A (en) Assay of Anti-Free-S- Antibodies
AU567747B2 (en) Early detection of mammalian pregnancy
CA2178635A1 (en) Immunofluorescence assay for the detection of antibodies using recombinant antigens in insoluble form
WO1999043703A8 (en) Method for immunochemically assaying anti-hm1.24 antibody
EP0368273A3 (en) New method of assay for antigen
EP0293827A3 (en) Assay for leishmaniasis
AU635243B2 (en) Immunoassay of human osteocalcin, reagent and kit therefor, antihuman osteocalcin antibody, hybridoma producing said antibody, and method of producing said antibody
ATE90790T1 (en) PROCESS FOR MAKING A SOLID PHASE MATRIX.
CA2213083A1 (en) Detection of antibody production
EP0487621A4 (en) Immunoassay of glycosylated proteins employing antibody directed to reductively glycosylated n-terminal amino acids
DK0418590T3 (en) Antibodies, their preparation and their use
FR2663034B1 (en) PEPTIDES OF THE SM-D ANTIGEN AND THEIR USE IN PARTICULAR FOR THE DIAGNOSIS OF DISSEMINED LUPUS ERYTHEMATOUS.
EP0303980A3 (en) Carrier coated with antigen or antibody
EP0324969A3 (en) Method of measuring transferrin
CA2006474A1 (en) Geminal diphenyl derivatives and their use in immunoassays
CA2140921A1 (en) Method and kit for pyridinium crosslink assay
AU6189486A (en) Monoclonal antibodies to prosomal proteins
CA2250047A1 (en) Monoclonal antibodies binding human growth hormone (hgh)

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20131202